Biomarkers and Genomic Testing
Tools You Can Use
Liquid Biopsy/ctDNA Testing: Signatera
Liquid Biopsy/ctDNA (for MRD) Testing: Guardant Reveal
Liquid Biopsy/ctDNA Testing: Guardant360®
Tissue Testing: Immunoscore®
Questions? Feedback?

What do my results mean?

Guardant Reveal is a test designed to detect the presence of remaining cancer after surgery and to detect cancer that is coming back after the end of cancer treatment.

positive or “ctDNA detected” result means that there is evidence of remaining cancer in your body and that your risk for cancer recurrence (cancer coming back) is high. In one study published in the journal Clinical Cancer Research, all patients with colon or rectal cancer who tested positive by Guardant Reveal after the end of treatment recurred if they had at least one year of follow-up.*

negative or “ctDNA not detected” result means that no residual or remaining cancer was detected by the test. While this doesn’t rule out the possibility that your cancer will come back, studies have shown that patients who are ctDNA negative after the end of treatment have a lower chance for recurrence.*

*Parikh et al. Minimal Residual Disease Detection using a Plasma-only Circulating Tumor DNA Assay in Patients with Colorectal Cancer Clinical Cancer Research 2021

Sample reports

Sample positive report, post-surgery setting
Sample positive report, surveillance setting
Sample negative report, post-surgery setting
Sample negative report, surveillance setting